David A. Cole specializes in creating the strategic and operational environments where medical innovation can successfully scale.
With a 15-year career defined by the industry's most seismic shifts, David specializes in bridging the structural gap between early-stage intellectual property and institutional adoption. His builder ethos allows him to transition seamlessly from the high-level strategy of multi-billion dollar mergers to the ground-level execution of internal startups and venture-backed solutions.
The foundation of David's approach was forged during the two largest consolidations in MedTech history. During the $20 billion Johnson & Johnson/Synthes merger, he navigated the evolution of orthopedics from a clinical discipline into a model of operational and reimbursement optimization. He later applied this mindset during the $42.9 billion Medtronic/Covidien acquisition, branding the endovascular pathway by managing the complex labor migration between Interventional Radiology, Neurosurgery, and Vascular Medicine to build the infrastructure for national Centers of Excellence.
Beyond strategy, David possesses a robust clinical pedigree that informs every commercial decision. By translating complex research into viable commercial engines, he successfully launched an internal startup within Medtronic's vascular division. Starting with zero infrastructure, he scaled the business to $100 million in annual revenue, transforming a niche procedure into a statewide clinical standard of care. This ability to unite disparate stakeholders also defined his recent venture into healthcare infrastructure, where he co-founded a software solution to solve the multibillion-dollar hospital inventory crisis by bridging the data gap between procurement and clinical records.
As Managing Partner of Ventrium Sciences and Biome Growth Partners, David serves as a central node in the global innovation ecosystem. He established the first MedTech Network of Networks, a framework designed to solve the chronic disconnect between university-level IP and the commercial resources required for global impact.
At Biome Growth Partners, David focuses on the critical zero-to-one phase of biotechnology and medical device development. He works with early-stage founders to de-risk clinical pathways, secure strategic partnerships, and design the commercial architecture necessary for institutional exit. By aligning world-class clinical expertise with sophisticated market-building strategies, David ensures that the next generation of life-saving technology has a clear, unobstructed pathway from the laboratory to the patient.
